No Data
Jinhai Medical Partners With Sinopharm for China Expansion
JINHAI MED TECH (02225.HK) has signed a master sales agreement with China National Pharmaceutical Group.
On January 3, Gelonghui reported that JINHAI MED TECH (02225.HK) announced that its wholly-owned subsidiary Shanghai JINHAI Xiehuan Medical Technology Co., Ltd. ("JINHAI Xiehuan") has recently entered into a total sales agreement with SINOPHARM Lingshang Hospital Management Service (Shanghai) Co., Ltd. ("SINOPHARM Lingshang"). According to this agreement, JINHAI Xiehuan authorizes SINOPHARM Lingshang as the exclusive distributor for several high-end medical instruments of the group in China, valid until October 2025. SINOPHARM Lingshang is a joint venture established by SINOPHARM and Mitsubishi Corporation of Japan. As a comprehensive operation service provider for medical consumables, SINOPHARM.
Express News | Jinhai Medical Technology - Unit Authorized Sinopharm Lingshang as Exclusive Distributor of Certain High-Ended Medical Devices in PRC up to Oct
SINOPHARM (01099.HK) received a Shareholding of 0.2312 million shares from CITIC SEC.
On December 31, according to the latest equity disclosure data from the Stock Exchange, on December 23, 2024, SINOPHARM (01099.HK) was increased by CITIC Securities Company Limited in the market, acquiring 231,200 shares at an average price of HKD 21.6569 per share, involving approximately HKD 5.0071 million. After the increase, the latest number of shares held by CITIC Securities Company Limited is 120,821,600 shares, with the shareholding ratio rising from 8.99% to 9.00%.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Is Sinopharm Group Co. Ltd.'s (HKG:1099) Recent Stock Performance Tethered To Its Strong Fundamentals?
Cui Nyonya Kueh :
Musang Siguntang : ???